Integration of hepatitis B virus into the human genome is a common occurrence in HBeAg-negative chronic infection
ILC 2019: Latest study suggests that integration of hepatitis B virus (HBV) DNA into the human genome is not restricted to the early phases of chronic HBV infection but also…
Givosiran and lanreotide produce encouraging results in studies of rare liver diseases
ILC 2019: Promising results reported with givosiran in acute hepatic porphyria (AHP) and lanreotide in polycystic liver disease (PLD) associated with autosomal dominant polycystic kidney disease (ADPKD) 13 April 2019,…
Tenofovir associated with a lower risk of hepatocellular carcinoma than entecavir in large hepatitis B study
ILC 2019: Study involving >29,000 individuals with chronic hepatitis B virus infection reports that the risk of hepatocellular carcinoma is at least one-third lower in those treated with tenofovir than…
‘Real-world’ effectiveness of elbasvir/grazoprevir confirmed in people with hepatitis C virus infection who inject drugs and/or receive opioid substitution therapy
ILC 2019: ‘Real-world’ studies confirm the effectiveness of elbasvir/grazoprevir in people with hepatitis C (HCV) genotype 1 infection who inject and/or abuse drugs or who receive opioid substitution therapy 13…
Burden of alcohol-related liver disease on the increase in Canada: are alcohol harm reduction strategies failing?
ILC 2019: Population-based study finds ‘critical increase’ in the burden of cirrhosis due to alcohol-related liver disease in Canada, with rising prevalence rates, high rates of late diagnosis, and poor…